More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
A new brain imaging study is giving experts insight into how medication used to treat ADHD works in the brain to soften symptoms associated with the neurological disorder.
New research published in Annals of Rheumatic Diseases and Hypertension examined the impact medications for different non-cardiovascular conditions can have on a patient's heart health.
Common markers of Alzheimer's disease visualized on PET scans of asymptomatic patients might foreshadow the onset of symptoms in the years following their initial discovery.
Researchers have completed a new analysis of the Evolut Pro and Pro+ devices from Medtronic and the Sapien 3 Ultra devices from Edwards Lifesciences, sharing the results in JACC: Cardiovascular Interventions.
A large academic medical center launched a virtual radiology reading room in 2020 to comply with COVID-related social distancing guidelines. Today the room is still something of a hit.
The study, which was published in Brain and Behavior, found that individuals who used their smartphone excessively displayed different strengths in the prefrontal and parietal neural network.
